emovis is honored and motivated to be considered one of the preferred partners by recognized CROs and sponsors. The CROs include Quintiles and PAREXEL, as well as the sponsor Pfizer in these partnerships. emovis is always interested in being the first choice for other sponsors of important sites.
emovis has been a part of PAREXEL’s "Site Alliance Networks" since 2015. The "Site Alliance Network" of PAREXEL consists of 300 members and additional SMOs. Collaboratively, this network grants access to approximately 6,000 investigators worldwide. The SMOs alone have access to a total of approximately 7.5 million patients in more than 20 countries. This partnership is also a constant motivating factor for emovis to improve on an even greater level.
emovis has been admitted to the INSPIRE Program by Pfizer in 2013. INSPIRE stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence. Participating in INSPIRE enables emovis to gain early insight in the PFIZER portfolio and access extensive information on clinical trials sponsored by Pfizer.
The special relationship with Quintiles has been in existence for more than 10 years. emovis was admitted to the "Selected Sites" back then and the partnership has continued without changes.
Be the first to hear news at emovis. Join the exclusive circle of B2B-newsletter subscribers.Subscribe now